Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
12 participants
INTERVENTIONAL
2006-08-31
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
NCT01040871
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT00312845
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
NCT00085696
Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL
NCT00151320
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
NCT01281917
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Velcade, Rituximab,Cyclophosphamide & Decadron
Velcade 375 mg/m\^2 given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
VELCADE®
1.6 mg/m\^2 of Velcade® given intravenously on days 1, 8, 15 and 22.
Rituximab
375 mg/m\^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
Cyclophosphamide
400 mg/m\^2 of Cyclophosphamide given orally on days 1-4 of each cycle.
Decadron
40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VELCADE®
1.6 mg/m\^2 of Velcade® given intravenously on days 1, 8, 15 and 22.
Rituximab
375 mg/m\^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
Cyclophosphamide
400 mg/m\^2 of Cyclophosphamide given orally on days 1-4 of each cycle.
Decadron
40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Follicular Cell Lymphoma (grades I and II)
* Mantle Cell Lymphoma patients that are not considered eligible for high-dose therapy and stem cell transplant
* Lymphoplasmacytic lymphoma including Waldenstrom's Macroglobulinemia
* Marginal Zone Lymphoma
* MALT Lymphoma that has ONLY failed antibiotic therapy or involved field radiation.
* Adequate bone marrow function, renal function, and hepatic function as outlined in details below.
* ECOG performance status of 0, 1, or 2
* Able to read, understand, and sign an IRB approved informed consent
Exclusion Criteria
* Known CNS involvement
* Prior therapy for lymphoma EXCLUDING antibiotic treatment for MALT-Type NHL.
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Millennium Pharmaceuticals, Inc.
INDUSTRY
Oncology Specialists, S.C.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Sigrun Hallmeyer
Director of Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chadi Nabhan, MD
Role: PRINCIPAL_INVESTIGATOR
Oncology Specialists, SC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Onocology Specialists, S.C
Niles, Illinois, United States
Oncology Specialists, S.C
Park Ridge, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0606
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.